GT200500049A - DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS - Google Patents
DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERSInfo
- Publication number
- GT200500049A GT200500049A GT200500049A GT200500049A GT200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A GT 200500049 A GT200500049 A GT 200500049A
- Authority
- GT
- Guatemala
- Prior art keywords
- naftiridine
- derivatives
- diabetes
- related disorders
- treat diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL I EN LA QUE R1,R2,R3,R4,R5,R6,R7, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON DE UTILIDAD PARA TRATAR O PREVENIR PATOLOGIAS TALES COMO LA DIABETES DE TIPO 1 O TIPO 2, DIABETES JUVENIL DE INICIO EN LA MADUREZ, DIABETES AUTOINMUNE DEL ADULTO PRINCIPALMENTE. T2005THIS INVENTION CONCERNS COMPOUNDS OF GENERAL FORMULA I IN WHICH R1, R2, R3, R4, R5, R6, R7, ARE FUNCTIONAL GROUPS DESCRIBED IN THE RECORD. THESE COMPOUNDS ARE USEFUL TO TREAT OR PREVENT PATHOLOGIES SUCH AS DIABETES OF TYPE 1 OR TYPE 2, YOUTH STARTING DIABETES IN MATURITY, DIABETES AUTOINMUNE OF THE ADULT MAINLY. T2005
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55297104P | 2004-03-12 | 2004-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200500049A true GT200500049A (en) | 2005-10-24 |
Family
ID=35056657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200500049A GT200500049A (en) | 2004-03-12 | 2005-03-11 | DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR048088A1 (en) |
| GT (1) | GT200500049A (en) |
| PE (1) | PE20060332A1 (en) |
| TW (1) | TW200538124A (en) |
| UY (1) | UY28805A1 (en) |
| WO (1) | WO2005091857A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015917A2 (en) * | 2007-05-14 | 2009-02-05 | F. Hoffmann-La Roche Ag | Dihydroquinone and dihydronaphthridine inhibitors of jnk |
| SI2448938T1 (en) | 2009-06-29 | 2014-08-29 | Incyte Corporation Experimental Station | Pyrimidinones as pi3k inhibitors |
| FR2952934B1 (en) * | 2009-11-23 | 2012-06-22 | Sanofi Aventis | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| US20130197043A1 (en) | 2010-08-31 | 2013-08-01 | Snu R&Db Foundation | Use of the fetal reprogramming of a ppar agonist |
| JP5961187B2 (en) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | N- (1- (substituted phenyl) ethyl) -9H-purin-6-amine as a PI3K inhibitor |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| EP2731932B1 (en) * | 2011-07-12 | 2015-12-30 | F.Hoffmann-La Roche Ag | Aminomethyl quinolone compounds |
| DK3196202T3 (en) | 2011-09-02 | 2019-05-13 | Incyte Holdings Corp | HETEROCYCLYLAMINS AS PI3K INHIBITORS |
| AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| PH12017501538B1 (en) | 2015-02-27 | 2024-02-14 | Incyte Holdings Corp | Salts of p13k inhibitor and processes for their preparation |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2018102885A1 (en) * | 2016-12-09 | 2018-06-14 | Bionomics Limited | Modulators of nicotinic acetylcholine receptors and uses thereof |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| JOP20180097B1 (en) * | 2018-10-22 | 2023-03-28 | Univ Of Jordan | 1,8-naphthyridine gluosamine derivatives,their use in the treatment of microbial infections,and amethod for preparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL51092A0 (en) * | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
| US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
-
2005
- 2005-02-24 WO PCT/US2005/005367 patent/WO2005091857A2/en active Application Filing
- 2005-03-10 AR ARP050100921A patent/AR048088A1/en unknown
- 2005-03-11 UY UY28805A patent/UY28805A1/en not_active Application Discontinuation
- 2005-03-11 GT GT200500049A patent/GT200500049A/en unknown
- 2005-03-11 PE PE2005000284A patent/PE20060332A1/en not_active Application Discontinuation
- 2005-03-11 TW TW094107389A patent/TW200538124A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005091857A3 (en) | 2006-10-05 |
| UY28805A1 (en) | 2005-09-30 |
| TW200538124A (en) | 2005-12-01 |
| WO2005091857A2 (en) | 2005-10-06 |
| AR048088A1 (en) | 2006-03-29 |
| PE20060332A1 (en) | 2006-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200500049A (en) | DERIVATIVES OF 1,6-NAFTIRIDINE AND 1,8-NAFTIRIDINE AND ITS USE TO TREAT DIABETES AND RELATED DISORDERS | |
| GT200500242A (en) | PROCESSES FOR THE PREPARATION OF 2- (2,6-DIOXOPIPERIDIN-3-IL) -1-SUBSTITUTED OXOISOINDOLINES | |
| CL2008000212A1 (en) | COMPOUNDS DERIVED FROM PHENOTIAZINE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT DIABETES, REDUCE THE LEVELS OF GLUCEMIA, ADDICTION TO NICOTINE, ADDICTION TO ALCOHOL, DISORDERS OF THE CENTRAL NERVOUS SYSTEM, BETWEEN | |
| GT200600197A (en) | COMPOUNDS AND COMPOSITIONS AS PROTEIN QUINASA INHIBITORS | |
| ECSP088283A (en) | PIRIDINE COMPOUNDS 5- (PHENYLISOXAZOLILETOXI) -TRIAZOL- 3-ILO SUBSTITUTED FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | |
| GT200600167A (en) | DERIVATIVES OF DIHYDROBENZOFURAN AND USES OF THE SAME | |
| BRPI0411528A (en) | use of isomalt as prebiotic | |
| GT200600011A (en) | PROCEDURES TO PREPARE ETERES OF PIRAZOLO [3,4-D] PYRIMIDINE | |
| CR10852A (en) | BICYCLE COMPOUNDS AND ITS USE AS ANTI-DIABETICS | |
| ECSP109921A (en) | SULFONAMIDS AS TRPM8 MODULATORS | |
| GT200500208A (en) | USEFUL INDAZOLS TO TREAT CARDIOVASCULAR DISEASES | |
| GT200600161A (en) | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | |
| NO20090029L (en) | Pyrrolopyrimidines for Pharmaceutical Formulations | |
| GT200300219A (en) | TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| UY32312A (en) | 4-AZETIDINIL-1-HETEROARIL-CICLOHEXANOL ANTAGONISTS OF CCR2 | |
| CR10682A (en) | TIAZOL PIRAZOLOPIRIMIDINE COMPOUNDS | |
| MY143241A (en) | 3, 5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission | |
| EA200801220A1 (en) | 3-AMINOCYCLOPENTANECARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS | |
| ECSP055964A (en) | HETEROCICLIL-3-SULPHONYLINDAZOLS AS LIGANDS OF 5-HYDROXYTHYRIPTAMINE-6 | |
| BRPI0511907A (en) | new disubstituted phenylpiperidine / piperizine derivatives as modulators of dopamine neurotransmission | |
| GT200600017A (en) | 4-SUBSTITUTED PHENYLTHETHYROCHINOLINES, PROCESS FOR PREPARATION, USE AS A MEDICINAL PRODUCT AND MEDICINAL PRODUCT | |
| SE0401465D0 (en) | New substituted piperdines as modulators of dopamine neurotransmission | |
| EA200602242A1 (en) | 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS | |
| CR11273A (en) | DERIVADOS-2-ONA DISSTITUTED IN 3, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| CO6470792A2 (en) | ARILSULFONAMIDE 2.5-DISPOSED CCR3 ANTAGONISTS |